Lipella Pharmaceuticals (LIPO) Competitors $2.61 +0.04 (+1.56%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends LIPO vs. PMCB, SLGL, WENA, AWH, IMNN, IPA, CRVO, RLMD, TLPH, and KZIAShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), Aspira Women's Health (AWH), Imunon (IMNN), ImmunoPrecise Antibodies (IPA), CervoMed (CRVO), Relmada Therapeutics (RLMD), Talphera (TLPH), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. PharmaCyte Biotech Sol-Gel Technologies ANEW Medical Aspira Women's Health Imunon ImmunoPrecise Antibodies CervoMed Relmada Therapeutics Talphera Kazia Therapeutics PharmaCyte Biotech (NASDAQ:PMCB) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts rate PMCB or LIPO? Lipella Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 513.03%. Given Lipella Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Lipella Pharmaceuticals is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, PMCB or LIPO? PharmaCyte Biotech has higher earnings, but lower revenue than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.533.09Lipella Pharmaceuticals$483.53K6.53-$4.62M-$4.25-0.61 Is PMCB or LIPO more profitable? PharmaCyte Biotech has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -882.82%. PharmaCyte Biotech's return on equity of 1.38% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 1.38% 0.71% Lipella Pharmaceuticals -882.82%-192.33%-154.24% Which has more volatility and risk, PMCB or LIPO? PharmaCyte Biotech has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Does the MarketBeat Community favor PMCB or LIPO? Lipella Pharmaceuticals received 1 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/ALipella PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals believe in PMCB or LIPO? 34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 1.0% of PharmaCyte Biotech shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to PMCB or LIPO? In the previous week, PharmaCyte Biotech and PharmaCyte Biotech both had 1 articles in the media. PharmaCyte Biotech's average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PharmaCyte Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipella Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryLipella Pharmaceuticals beats PharmaCyte Biotech on 8 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.6110.5990.0517.18Price / Sales6.53195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.605.094.784.78Net Income-$4.62M$151.83M$120.31M$225.60M7 Day Performance2.76%-2.13%-1.92%-1.23%1 Month Performance7.85%-3.10%11.50%3.36%1 Year Performance-63.51%11.54%30.59%16.60% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals3.1489 of 5 stars$2.61+1.6%$16.00+513.0%-63.5%$3.16M$483,533.00-0.614PMCBPharmaCyte Biotech0.4217 of 5 stars$1.66-3.5%N/A-24.8%$12.75MN/A2.612Earnings ReportSLGLSol-Gel Technologies2.4245 of 5 stars$0.45-5.3%$5.00+1,000.6%-66.5%$12.66M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAWHAspira Women's Health1.218 of 5 stars$0.74-1.3%$4.40+494.7%-69.7%$12.33M$9.15M-0.62110Analyst ForecastIMNNImunon2.3546 of 5 stars$0.84-0.5%$20.50+2,340.5%+9.2%$12.18M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpIPAImmunoPrecise Antibodies2.9227 of 5 stars$0.42+4.1%$5.00+1,090.5%-69.5%$12.11M$24.07M-0.5280News CoverageCRVOCervoMed2.1768 of 5 stars$1.93+1.6%$42.00+2,076.2%-67.1%$11.91M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeRLMDRelmada Therapeutics4.19 of 5 stars$0.39+5.9%$4.25+994.0%-87.7%$11.72MN/A-0.1310Gap DownHigh Trading VolumeTLPHTalphera2.886 of 5 stars$0.67+2.9%$4.50+572.6%N/A$11.39M$281,000.00-0.9419Positive NewsKZIAKazia Therapeutics1.7318 of 5 stars$3.41-3.9%$20.00+486.5%-21.6%$11.35M$2.31M0.0012Gap Up Related Companies and Tools Related Companies PMCB Competitors SLGL Competitors WENA Competitors AWH Competitors IMNN Competitors IPA Competitors CRVO Competitors RLMD Competitors TLPH Competitors KZIA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LIPO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
